In this amendment, claim 6 is cancelled without prejudice and claim 1 is amended. Support for the amendment can be found in the specification and original claims. For example, Kex 2 enzymatic activity is disclosed at page 2, lines 23-26. No new matter is added. Accordingly, claims 1-5 and 7-10 are pending and at issue.

It is believed that the claims are in condition for allowance, and a determination to that effect is earnestly solicited.

Date: February 15, 2002

Respectfully submitted,

Reza Green, Reg. No. 38,475

Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400

New York, NY 10174-6401


(212) 867-0123

23650

PATENT TRADEMARK OFFICE

FEB 2 8 2002 WARKED-UP VERSION OF CLAIM SHOWING CHANGES

1. (Amended) A method for producing Factor VII comprising (a) cultivation of a mammalian cell line comprising a DNA sequence encoding a yeast-derived endoprotease having Kex2 enzymatic activity [or a derivative thereof] and a DNA sequence encoding Factor VII (FVII) in a suitable culture medium, under conditions in which both said endoprotease and said FVII are expressed; and (b) isolation of Factor VII from the medium.





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wöldike et al.

Serial No.: 10/044,426

Group Art Unit: To be assigned

Filed: November 13, 2001

Examiner: To be assigned

For: Method For The Production Of FVII

## **CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents Washington, DC 20231

RECEIVED

APR 0 1 2002

Fishberg

Sir:

I hereby certify that the attached correspondence comprising: TECH CENTER 1600/2900

- 1. Supplemental Preliminary Amendment No Fee Transmittal
- 2. Supplemental Preliminary Amendment

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents Washington, DC 20231

on February 15, 2002.

Carol McFarlane-Fishberg (name of person mailing paper)

(signature of person mailing paper)

23650

PATENT TRADEMARK OFFICE